Remove Clinical Supply Remove Drug Development Remove Licensing
article thumbnail

A Closer Look At Our On-Site Compounding Pharmacies

Alta Sciences

Regulatory Excellence - Licenses for Schedule I through IV drug substances. Adherence to harmonized pharmacy-specific SOPs based on cGMP principles at our three clinical pharmacology units. Electronic security access to the pharmacy and video monitoring. - 24/7 monitoring of temperature and humidity.

article thumbnail

Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19

The Pharma Data

Novartis has been granted an option to in-license global rights of MP0420 and MP0423 – multi-targeted direct-acting antiviral therapeutic candidates demonstrating potential efficacy against COVID-19. Upon option exercise, Novartis would be responsible for all further development and commercialization activities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The golden era of GLP-1 drugs: How will it impact medicine and society?

BioPharma Drive: Drug Pricing

However, with this kind of promise comes more scientific, ethical and financial questions that healthcare providers and drug development professionals must seriously consider. As more people take them and their uses grow, so does their potential.

article thumbnail

FDA’s AI tool ‘Elsa’ is here, and the industry has questions

BioPharma Drive: Drug Pricing

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from FDA’s AI tool ‘Elsa’ is here, and the industry has questions The agency has provided only limited details about its AI pilot as it advances an “aggressive timeline” for the tool’s rollout.

FDA 130